Researchers from Boston Medical Center, Boston University, the University of Pittsburgh School of Medicine, the University of Pennsylvania, and Acuitas Therapeutics (Vancouver, BC) have found evidence that a novel stem cell treatment, using mRNA technology encapsulated into nanoparticles – which was successfully used to produce COVID-19 vaccine – may boost the natural repair mechanism of the liver to regress the diseased tissue caused by either an acute or chronic liver injury. "This potential treatment has important clinical implications for people suffering from chronic liver disease, allowing the liver to heal itself, and potentially avoiding the need for many liver transplants," said Valerie Gouon-Evans, the corresponding author of the study. "It's our hope that these findings, with further study, will be translated to clinical patient care to alleviate chronic liver disease and the need for transplants as a result of acute or chronic injury."
An official website of the United States government.